{"id":"https://openalex.org/W2790785690","doi":"https://doi.org/10.1200/jco.2018.36.6_suppl.302","title":"Activity of VERU-111, an novel oral \u03b1 and \u03b2 tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer.","display_name":"Activity of VERU-111, an novel oral \u03b1 and \u03b2 tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer.","publication_year":2018,"publication_date":"2018-02-20","ids":{"openalex":"https://openalex.org/W2790785690","doi":"https://doi.org/10.1200/jco.2018.36.6_suppl.302","mag":"2790785690"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.6_suppl.302","doi":"https://doi.org/10.1200/jco.2018.36.6_suppl.302","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.6_suppl.302","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000390933","display_name":"Robert H. Getzenberg","orcid":"https://orcid.org/0000-0003-0104-8391","observed_orcids":["https://orcid.org/0000-0003-0104-8391"]},"institutions":[{"id":"https://openalex.org/I4405267815","display_name":"Veru Inc. (United States)","ror":"https://ror.org/04grqb131","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert H. Getzenberg","raw_affiliation_strings":["Veru Inc, Miami, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Veru Inc, Miami, FL;","institution_ids":["https://openalex.org/I4405267815"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002243266","display_name":"James T. Dalton","orcid":"https://orcid.org/0000-0002-3915-7326","observed_orcids":["https://orcid.org/0000-0002-3915-7326"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James T. Dalton","raw_affiliation_strings":["University of Michigan College of Pharmacy, Ann Arbor, MI;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan College of Pharmacy, Ann Arbor, MI;","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016676195","display_name":"Duane D. Miller","orcid":"https://orcid.org/0000-0002-6093-0985","observed_orcids":["https://orcid.org/0000-0002-6093-0985"]},"institutions":[{"id":"https://openalex.org/I160606119","display_name":"University of Tennessee Health Science Center","ror":"https://ror.org/0011qv509","country_code":"US","type":"education","lineage":["https://openalex.org/I160606119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Duane D. Miller","raw_affiliation_strings":["UT School of Pharmacy, Memphis, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT School of Pharmacy, Memphis, TN;","institution_ids":["https://openalex.org/I160606119"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078595899","display_name":"Mitchell S. Steiner","orcid":"https://orcid.org/0000-0002-3492-7678","observed_orcids":["https://orcid.org/0000-0002-3492-7678"]},"institutions":[{"id":"https://openalex.org/I4405267815","display_name":"Veru Inc. (United States)","ror":"https://ror.org/04grqb131","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267815"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mitchell S. Steiner","raw_affiliation_strings":["Veru Inc, Miami, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Veru Inc, Miami, FL;","institution_ids":["https://openalex.org/I4405267815"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"6_suppl","first_page":"302","last_page":"302"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9394999742507935,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9394999742507935,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.04899999871850014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/paclitaxel-resistance","display_name":"paclitaxel resistance","score":0.9399999976158142},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.6930000185966492},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.8240000009536743},{"id":"https://openalex.org/keywords/taxane-resistance","display_name":"taxane resistance","score":0.6919999718666077},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6830000281333923},{"id":"https://openalex.org/keywords/pc-3-cells","display_name":"PC-3 cells","score":0.6809999942779541},{"id":"https://openalex.org/keywords/hormone-sensitive-prostate-cancer","display_name":"hormone-sensitive prostate cancer","score":0.6740000247955322},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9580000042915344},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.8009999990463257},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.7300000190734863},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5820000171661377},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.7329999804496765}],"concepts":[{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.9289445877075195},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.8888119459152222},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.8016712069511414},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7435235381126404},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7084305286407471},{"id":"https://openalex.org/C2780201970","wikidata":"https://www.wikidata.org/wiki/Q412939","display_name":"Estramustine","level":5,"score":0.6016077399253845},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.549509584903717},{"id":"https://openalex.org/C2776235491","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate","level":3,"score":0.5053389668464661},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.48615190386772156},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4193209707736969},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.1292944848537445},{"id":"https://openalex.org/C2994223898","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate disease","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.6_suppl.302","doi":"https://doi.org/10.1200/jco.2018.36.6_suppl.302","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.6_suppl.302","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2796461696","https://openalex.org/W2891245224","https://openalex.org/W2921696673","https://openalex.org/W2940635682","https://openalex.org/W2793541759","https://openalex.org/W2921352214","https://openalex.org/W2921729087","https://openalex.org/W3085018801","https://openalex.org/W3088718403","https://openalex.org/W4240512121"],"abstract_inverted_index":{"302":[0],"Background:":[1],"Following":[2],"proven":[3],"efficiacy":[4],"of":[5,19,24,38,47,50,91,118,201,234],"docetaxel":[6,20,126,212,219],"against":[7],"hormone":[8,25,302],"sensitive":[9,26,303],"advanced":[10,307],"prostate":[11,31,41,308],"cancer":[12,32,42],"(CHAARTED":[13],"and":[14,27,57,70,88,97,128,168,180,183,242,271,283,304,322],"STAMPEDE":[15],"studies),":[16],"the":[17,22,36,48,52,58,86,190,202,210,215,259],"use":[18],"for":[21,54,102,109,177,301],"treatment":[23,60],"castrate":[28,305],"resistant":[29,139,306],"metastatic":[30],"has":[33,43,288],"increased.":[34],"Unfortunately,":[35],"utility":[37],"taxanes":[39],"in":[40,123,132,137,199,230],"been":[44],"limited":[45],"because":[46],"development":[49],"resistance,":[51],"need":[53],"IV":[55,211,218],"infusion,":[56],"associated":[59],"toxicity.":[61],"VERU-111":[62,93,119,144,228,263,277,310],"is":[63,98,278],"a":[64,76,100,106,129,279,298,336],"highly":[65],"orally":[66],"available,":[67],"novel":[68],"\u03b1":[69,87,282],"\u03b2":[71,89,284],"tubulin":[72,95,285],"inhibitor,":[73],"developed":[74],"using":[75],"rationale":[77],"design":[78],"strategy":[79],"to":[80,85,296,342],"bind":[81],"through":[82],"hydrogen":[83],"bonds":[84],"subunits":[90],"tubulin.":[92],"inhibits":[94],"polymerization":[96],"not":[99,265,324],"substrate":[101],"multi-drug":[103],"resistance":[104],"proteins,":[105],"common":[107],"mechanism":[108],"taxane":[110],"resistance.":[111],"Methods:":[112],"In":[113,189,214,255],"this":[114,345],"study,":[115],"dosing":[116],"regimens":[117],"(oral)":[120,131],"were":[121,175,186],"tested":[122],"comparison":[124],"with":[125,196,262,314,335],"(IV)":[127],"vehicle":[130],"PC3":[133,140],"as":[134,136,248,250,316,318],"well":[135,249],"paclitaxel":[138],"(PC3-TXR).":[141],"xenograft":[142],"models.":[143],"was":[145],"evaluated":[146],"at":[147,237],"3.3":[148,238],"mg/kg":[149,153,157,163,170,239,244,252],"(5":[150,240],"days/week),":[151,155],"10":[152,243],"(3":[154,164,245],"15":[156,162],"(2":[158],"days":[159,165,179],"per":[160,166,320],"week),":[161],"week)":[167,247],"20":[169,251],"(1":[171,253],"day/week).":[172,254],"The":[173],"animals":[174,194,260],"treated":[176,195,261],"28":[178],"tumor":[181,224,235],"volume":[182],"percentage":[184],"size":[185],"calculated.":[187],"Results:":[188],"parental":[191],"PC-3":[192],"model,":[193,217],"oral":[197,227,281],"VERU-111,":[198],"all":[200],"dose":[203],"schemes":[204],"tested,":[205],"performed":[206,334],"statistically":[207],"indistinguishably":[208],"from":[209],"administration.":[213],"PC3-TXR":[216],"had":[220],"no":[221],"impact":[222],"on":[223],"growth":[225,236],"whereas":[226],"resulted":[229],"almost":[231],"complete":[232],"inhibition":[233],"days/week)":[241],"days/":[246],"early":[256],"toxicity":[257,329],"studies,":[258],"did":[264],"suffer":[266],"any":[267],"significant":[268],"safety":[269],"signals":[270],"gained":[272],"weight":[273],"during":[274],"treatment.":[275],"Conclusions:":[276],"novel,":[280],"inhibitor":[286],"that":[287],"drug":[289],"characteristics":[290],"making":[291],"it":[292],"an":[293],"ideal":[294],"candidate":[295],"be":[297,312],"therapeutic":[299],"option":[300],"cancer.":[309],"can":[311],"administered,":[313],"efficacy,":[315],"infrequent":[317],"once":[319],"week":[321],"will":[323],"require":[325],"daily":[326],"dosing.":[327],"Additional":[328],"studies":[330],"are":[331],"currently":[332],"being":[333,340],"Phase":[337],"1/2":[338],"study":[339],"planned":[341],"begin":[343],"later":[344],"year.":[346]},"counts_by_year":[],"updated_date":"2026-09-22T17:25:34.749102","created_date":"2018-03-29T00:00:00"}